In this new paper, Galen Senior Fellow Brian Blase explains that greater transparency in health care pricing will help employers to offer better payment structures for their employees and give employees and other consumers more tools to get better value in health spending. Price transparency should also will give employers the ability to monitor insurer effectiveness and eliminate … [Read more...] about Transparent Prices Will Help Consumers and Employers Reduce Health Spending
Surprise Billing Answers
One item on voters’ short list for congressional action is addressing the growing problem of surprise medical bills. Insured patients should be confident that if they receive care at a facility that is in their health plan’s network or have a medical emergency, they will be responsible only for their share of the plan’s negotiated rates. But all too often, a patient receives a bill … [Read more...] about Surprise Billing Answers
We Are Making Progress
Forbes, October 4, 2019 | In a major health care speech in Florida on October 3, President Trump outlined plans to bring Medicare into the 21 century. This is the best answer so far to Medicare for All by showing the clear contrast between bills that would put all Americans onto one centrally-run government program and efforts to modernize the existing Medicare program. The … [Read more...] about We Are Making Progress
This Senate Measure Would Restrict Health Care Choices and Raise Premiums
The Senate is expected to vote soon on a resolution aimed at curbing the president’s efforts to reduce health care premiums and expand insurance options for Americans. Sen. Mark Warner, D-Va., authored the resolution, which would curtail an administration initiative that was the driving force behind the first-ever reduction in average Obamacare premiums: the authority to grant states … [Read more...] about This Senate Measure Would Restrict Health Care Choices and Raise Premiums
Why Pelosi’s Drug Price Control Scheme Would Be a Poison Pill to Innovation and Access
The House of Representatives this week will begin acting on a bill that would limit Americans’ access to lifesaving medicines, impede the development of new treatments for deadly and debilitating diseases, and increase health spending over the long term. The Lower Drug Costs Now Act of 2019 (H.R. 3), introduced last week with the backing of House Speaker Nancy Pelosi, D-Calif., would double … [Read more...] about Why Pelosi’s Drug Price Control Scheme Would Be a Poison Pill to Innovation and Access